PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10496355-4 1999 The effect of aspirin on Annexin V binding was inhibited by the caspase inhibitor Z-VAD.fmk, indicating the involvement of caspases in the apoptotic action of aspirin. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 82-91 annexin A5 Homo sapiens 25-34 20104024-5 2010 ABT-737 synergistically enhanced celecoxib-induced cytotoxicity that was primarily due to apoptosis as shown by caspase cleavage and Annexin V labeling that was attenuated by a pan caspase inhibitor (z-VAD-fmk). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 200-209 annexin A5 Homo sapiens 133-142 12065694-8 2002 Both DEVD-fmk and ZVAD-fmk completely inhibited caspase 3 activity but, like PFT, partially inhibited cisplatin-induced chromatin condensation, annexin V labeling, and DNA hypoploidy after 24 h. These data demonstrate that at least 50% of cisplatin-induced apoptosis in RPTC is mediated by p53 and that p53 activates caspase 3 independently of either caspase 9 or 8 or mitochondrial dysfunction. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 18-26 annexin A5 Homo sapiens 144-153 15028782-9 2004 Pretreatment with ZVAD-fmk inhibited cisplatin-induced annexin V staining in Caki-1, A172, and A549 cells but had no affect in L1210 cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 18-26 annexin A5 Homo sapiens 55-64 28222420-8 2017 The effect of Camalexin on annexin-V-binding was significantly blunted by removal of extracellular Ca2+, by kinase inhibitors staurosporine (1 microM) and chelerythrine (10 microM), as well as by caspase inhibitors zVAD (10 microM) and zIETD-fmk (50 microM). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 215-219 annexin A5 Homo sapiens 27-36 28214863-8 2017 Annexin-V-binding was significantly blunted by caspase inhibitor zVAD (10microM). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 65-69 annexin A5 Homo sapiens 0-9 10069579-6 1998 Pretreatment of the cultures with zVAD-fmk blocked annexin V binding induced by beta-amyloid and concanavalin A, suggesting that caspase activity was required. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 34-42 annexin A5 Homo sapiens 51-60 31490284-3 2020 Treatment with EX527 increased the number of apoptotic cells (Annexin V-fluorescein isothiocyanate/propidium iodide); pretreatment with the caspase inhibitor Z-VAD-FMK suppressed EX527-induced apoptosis, suggesting that EX527 induced caspase-dependent apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 158-167 annexin A5 Homo sapiens 62-71 28535537-10 2017 The effect of exemestane (40 microg/ml) on annexin-V-binding was significantly blunted by antioxidant N-acetylcysteine (1mM), but was not significantly modified by removal or increase of extracellular Ca2+, by p38 kinase inhibitor SB203580 (2 microM), casein kinase inhibitor D4476 (10 microM) and caspase inhibitor zVAD (10 microM). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 316-320 annexin A5 Homo sapiens 43-52 28793293-12 2017 The effect of temsirolimus on annexin-V-binding was significantly blunted but not abolished by removal of extracellular Ca2+ and by addition of staurosporine (1 microM) or chelerythrine (10 microM) but not significantly modified by addition of SB203580 (2 microM), D4476 (10 microM), or zVAD (10 microM). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 287-291 annexin A5 Homo sapiens 30-39 24030154-6 2013 However, the broad-range caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) fails to protect against BV6/DAC-induced cell death and even significantly increases the percentage of Annexin-V/propidium iodide double-positive cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 95-103 annexin A5 Homo sapiens 208-217 27960155-8 2016 The effect of ceritinib on annexin-V-binding was significantly blunted but not abolished by removal of extracellular Ca2+, by the kinase inhibitors staurosporine (1 microM), SB203580 (2 microM) and D4476 (10 microM), as well as by caspase inhibitor zVAD (10 microM). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 249-253 annexin A5 Homo sapiens 27-36 27978526-12 2016 The effect of bexarotene on annexin-V-binding was significantly blunted by removal of extracellular Ca2+ and by addition of D4476 (10 microM), but not by addition of staurosporine (1 microM), SB203580 (2 microM), or zVAD (10 microM). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 216-220 annexin A5 Homo sapiens 28-37 26963694-9 2016 The effect of Elvitegravir on annexin-V-binding was significantly blunted by removal of extracellular Ca2+, but not in the presence of p38 kinase inhibitor SB203580 (2 microM) or in the presence of pancaspase inhibitor zVAD (10 microM). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 219-223 annexin A5 Homo sapiens 30-39 27197532-13 2016 Moreover, the effect of Anidulafungin on annexin-V-binding was not paralleled by significant increase of ceramide abundance and was not significantly blunted by PKC inhibitor staurosporine (1 microM), casein kinase 1alpha inhibitor D4476 (10 microM) or pancaspase inhibitor zVAD (10 microM). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 274-278 annexin A5 Homo sapiens 41-50 27442249-10 2016 The effect of dolutegravir on annexin-V-binding was significantly blunted by removal of extracellular Ca2+, but was not significantly modified by protein kinase C inhibitor staurosporine (1 microM), p38 kinase inhibitor SB203580 (2 microM), casein kinase inhibitor D4476 (10 microM) or pancaspase inhibitor zVAD (10 microM). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 307-311 annexin A5 Homo sapiens 30-39 27855413-8 2016 The effect of Calyculin A on annexin-V-binding was significantly blunted by removal of extracellular Ca2+, by staurosorine (1 microM), SB203580 (2 microM), D4476 (10 microM), and zVAD (10 microM). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 179-183 annexin A5 Homo sapiens 29-38 26623018-6 2015 As co-treatment with the pan-caspase inhibitor Z-VAD-FMK changed the number of Annexin V-positive cells, this combination-induced apoptosis was considered caspase dependent. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 47-56 annexin A5 Homo sapiens 79-88 25279191-5 2014 This combination significantly induced apoptosis in cancer cells and this apoptosis was considered to be caspase-dependent, since the pan-caspase inhibitor Z-VAD-FMK reduced the number of Annexin V-positive cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 156-165 annexin A5 Homo sapiens 188-197 24874286-7 2014 Furthermore, gefitinib synergistically enhanced decitabine-induced cytotoxicity was primarily due to apoptosis as shown by Annexin V labeling that was attenuated by z-VAD-fmk, a pan caspase inhibitor. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 165-174 annexin A5 Homo sapiens 123-132 24722468-4 2014 Cells containing mutant p150glued aggregates underwent apoptosis that was characterized by an increase in cleaved caspase-3- or Annexin V-positive cells and was attenuated by both zVAD-fmk (a pan-caspase inhibitor) application and caspase-3 siRNA knockdown. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 180-188 annexin A5 Homo sapiens 128-137 22814298-8 2012 Sunitinib induced annexin-V-binding was slightly, but significantly blunted by removal of extracellular Ca(2+), by p38 kinase inhibitor SB203580 (10 microM) and by the pancaspase inhibitor zVAD (10 microM). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 189-193 annexin A5 Homo sapiens 18-27 21823219-11 2011 Annexin-V-binding was blunted by Ca(2+) removal, by the cation channel inhibitor amiloride (1 mM), by the protein kinase C inhibitor staurosporine (500 nM) but not by the pancaspase inhibitor zVAD (10 muM). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 192-196 annexin A5 Homo sapiens 0-9